-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Jointown announced that it has signed a strategic cooperation agreement with Tianfang Pharmaceutical, which will further integrate the resources of the two parties, create a multi-faceted and complex cooperation model, and lay the foundation for cooperation in centralized procurement
.
It is understood that through this cooperation, Tianfang Pharmaceutical can obtain its comprehensive network and distribution service support, market maintenance, information value-added services, and cooperation with related varieties of centralized procurement
.
Jointown can also take this cooperation to extensively carry out raw and auxiliary materials business, general agency sales, and self-operated cooperation in many aspects
.
According to the data, Tianfang Pharmaceutical is a large-scale comprehensive pharmaceutical enterprise integrating the production and sales of finished preparations, chemical synthesis raw materials and biological fermentation raw materials, and medical management, integrating science, industry, and trade
.
In the third batch of national centralized procurement, Tianfang Pharmaceutical's product metformin hydrochloride sustained-release tablets (0.
5g), finasteride tablets 1mg and 5mg won the bid
.
Jiuzhou Tong is a company whose core business is the wholesale and retail chain of medicines, medical devices and other products, as well as the production and research and development of medicines and related value-added services
.
The company is one of the three major pharmaceutical commercial distribution companies in the country, and one of the only two companies with a national network in the pharmaceutical commercial field
.
According to statistics, as of 2020, Jointown's business has covered 159,200 primary medical institutions, 9,175 private hospitals, 5,337 chain pharmacies and other physical end customers
.
The analysis believes that from the perspective of pharmaceutical companies, after centralized procurement, its products can achieve rapid growth in sales within a certain period of time, but it is always difficult to obtain in the out-of-hospital market
.
Therefore, in order to better help the bid-winning products increase sales channels, it is necessary to cooperate with pharmaceutical distribution companies
.
The cooperation between Tianfang Pharmaceutical and Ru Jiuzhou Tong is expected to realize the rapid opening of the out-of-hospital market and obtain sales channels such as pharmacies and clinics
.
In fact, Jointown has long established a precedent for its cooperation with a centralized procurement and bid-winning pharmaceutical company
.
On November 25, 2019, Jointown announced that the company and Zhejiang Huahai Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Huahai Pharmaceutical") holding subsidiary Zhejiang Huahai Pharmaceutical Sales Co.
, Ltd.
(hereinafter referred to as "Huahai Pharmaceutical") Sign the "Strategic Cooperation Framework Agreement"
.
Judging from the content of the agreement, Jointown is mainly to help Huahai Pharmaceuticals to increase the sales of its standard product Irbesartan tablets outside the scope of the expansion of centralized procurement, and to ensure the medical distribution guarantee for the provinces selected in the alliance's procurement
.
In the context of the normalization of centralized procurement, many pharmaceutical companies are actually feeling the pressure
.
The industry believes that in order to cope with the shrinking profits of generic drugs brought about by centralized procurement, pharmaceutical companies are exploring ways to break through
.
Among them, cooperation has long become an indispensable development method for pharmaceutical companies; at the same time, the "industry + commerce" cooperation model has gradually penetrated the industry
.
It is worth mentioning that in addition to group cooperation, many companies are also accelerating the pace of transformation and upgrading.
Some are increasing their research and development capabilities and reaping profits with the pricing power of original drugs; others are increasing digital investment.
Take digital medical care as an opportunity to extend to the medical service side
.
At the same time, in view of the rise of the consumer medical industry, some pharmaceutical companies are also participating in the "medicine + medical" dual track through mergers and acquisitions and product transformation
.
In the future, it is expected that pharmaceutical companies will actively adapt to meet changes, or there will be more different forms of cooperation and transformation models in the industry
.
.
It is understood that through this cooperation, Tianfang Pharmaceutical can obtain its comprehensive network and distribution service support, market maintenance, information value-added services, and cooperation with related varieties of centralized procurement
.
Jointown can also take this cooperation to extensively carry out raw and auxiliary materials business, general agency sales, and self-operated cooperation in many aspects
.
According to the data, Tianfang Pharmaceutical is a large-scale comprehensive pharmaceutical enterprise integrating the production and sales of finished preparations, chemical synthesis raw materials and biological fermentation raw materials, and medical management, integrating science, industry, and trade
.
In the third batch of national centralized procurement, Tianfang Pharmaceutical's product metformin hydrochloride sustained-release tablets (0.
5g), finasteride tablets 1mg and 5mg won the bid
.
Jiuzhou Tong is a company whose core business is the wholesale and retail chain of medicines, medical devices and other products, as well as the production and research and development of medicines and related value-added services
.
The company is one of the three major pharmaceutical commercial distribution companies in the country, and one of the only two companies with a national network in the pharmaceutical commercial field
.
According to statistics, as of 2020, Jointown's business has covered 159,200 primary medical institutions, 9,175 private hospitals, 5,337 chain pharmacies and other physical end customers
.
The analysis believes that from the perspective of pharmaceutical companies, after centralized procurement, its products can achieve rapid growth in sales within a certain period of time, but it is always difficult to obtain in the out-of-hospital market
.
Therefore, in order to better help the bid-winning products increase sales channels, it is necessary to cooperate with pharmaceutical distribution companies
.
The cooperation between Tianfang Pharmaceutical and Ru Jiuzhou Tong is expected to realize the rapid opening of the out-of-hospital market and obtain sales channels such as pharmacies and clinics
.
In fact, Jointown has long established a precedent for its cooperation with a centralized procurement and bid-winning pharmaceutical company
.
On November 25, 2019, Jointown announced that the company and Zhejiang Huahai Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Huahai Pharmaceutical") holding subsidiary Zhejiang Huahai Pharmaceutical Sales Co.
, Ltd.
(hereinafter referred to as "Huahai Pharmaceutical") Sign the "Strategic Cooperation Framework Agreement"
.
Judging from the content of the agreement, Jointown is mainly to help Huahai Pharmaceuticals to increase the sales of its standard product Irbesartan tablets outside the scope of the expansion of centralized procurement, and to ensure the medical distribution guarantee for the provinces selected in the alliance's procurement
.
In the context of the normalization of centralized procurement, many pharmaceutical companies are actually feeling the pressure
.
The industry believes that in order to cope with the shrinking profits of generic drugs brought about by centralized procurement, pharmaceutical companies are exploring ways to break through
.
Among them, cooperation has long become an indispensable development method for pharmaceutical companies; at the same time, the "industry + commerce" cooperation model has gradually penetrated the industry
.
It is worth mentioning that in addition to group cooperation, many companies are also accelerating the pace of transformation and upgrading.
Some are increasing their research and development capabilities and reaping profits with the pricing power of original drugs; others are increasing digital investment.
Take digital medical care as an opportunity to extend to the medical service side
.
At the same time, in view of the rise of the consumer medical industry, some pharmaceutical companies are also participating in the "medicine + medical" dual track through mergers and acquisitions and product transformation
.
In the future, it is expected that pharmaceutical companies will actively adapt to meet changes, or there will be more different forms of cooperation and transformation models in the industry
.
